Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2018-2020 - Global API Manufacturers, Marketed and Phase III Drugs Landscape Report - ResearchAndMarkets.com

Research and Markets
Posted on: 22 Feb 18

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Coverage of API manufacturers for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

Emerging Phase III products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This report provides a comprehensive understanding of the emerging Phase III therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

Other marketed products in the detailed report

5. Emerging Therapies (Phase III)

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

Other Phase III profiles in the detailed report

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5k5tcq/chronic?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006300/en/

Business Wire
www.businesswire.com

Last updated on: 22/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.